Explanipedia

Benefits and risks of FDA‐approved amyloid‐targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician‐patient engagement Open

Dorene M. Rentz, Paul Aisen, Alireza Atri, Janice M. Hitchcock, Michael C. Irizarry , et al. · 2024

The emergence of the United States Food and Drug Administration (FDA)‐approved amyloid‐targeting therapies for Alzheimer's disease challenges clinicians and healthcare providers with a transformative landscape. Effectively communicating th…

Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force Open

Davide Angioni, J Cummings, C.J. Lansdall, Lavinia P. Middleton, Cristina Sampaio , et al. · 2024

Recent positive results of three phase III anti-amyloid monoclonal antibody trials are transforming the landscape of disease-modifying therapeutics for Alzheimer's disease, following several decades of failures. Indeed, all three trials ha…

Response to van Dyck, O'Dell, & Mecca letter to the editor regarding Andrews et al. (2019) Open

J. Scott Andrews, Urvi Desai, Noam Y. Kirson, Brandy R. Matthews · 2023

In their letter to the editor, van Dyck et al. commented on our 2019 paper “Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials,”1 as well as its interpretat…

Expectations and clinical meaningfulness of randomized controlled trials Open

Ronald C. Petersen, Paul Aisen, J. Scott Andrews, Alireza Atri, Brandy R. Matthews , et al. · 2023

Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatmen…

The trend of disruption in the functional brain network topology of Alzheimer’s disease Open

Alireza Fathian, Yousef Jamali, Mohammad Reza Raoufy, Michael W. Weiner, Norbert Schuf , et al. · 2022

Alzheimer’s disease (AD) is a progressive disorder associated with cognitive dysfunction that alters the brain’s functional connectivity. Assessing these alterations has become a topic of increasing interest. However, a few studies have ex…

Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease Open

Tingxiang Yan, Jingjing Liang, Ju Gao, Luwen Wang, Hisashi Fujioka , et al. · 2022

The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision Making Open

Carol Mansfield, Kristin Bullok, Jillian Venci Fuhs, Antje Tockhorn‐Heidenreich, J. Scott Andrews , et al. · 2022

Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease Open

Julie Gonneaud, Alex T. Baria, Alexa Pichet Binette, Brian A. Gordon, Carlos Cruchaga , et al. · 2021

Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review Open

Élizabeth Leroux, Andrew Buchanan, Louise Lombard, Li Shen Loo, Daisy Bridge , et al. · 2020

Irrespective of the methodology or definition used to identify people with insufficient efficacy and/or tolerability to triptans, study results support the assertion that a high unmet need remains for effective acute treatment of migraine.

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies Open

Timothy R. Smith, John H. Krege, Suchitrita S. Rathmann, Sherie A. Dowsett, Ann Marie Hake , et al. · 2020

FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease Open

Tingxiang Yan, Jingjing Liang, Ju Gao, Luwen Wang, Hisashi Fujioka , et al. · 2020

Alzheimer’s disease (AD) is characterized by amyloid plaques and progressive cerebral atrophy. Here, we report FAM222A as a putative brain atrophy susceptibility gene. Our cross-phenotype association analysis of imaging genetics indicates …

A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data Open

Suprateek Kundu, Joshua Lukemire, Yikai Wang, Ying Guo, Michael W. Weiner , et al. · 2019

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease Open

Alette M. Wessels, Pierre N. Tariot, Jennifer A. Zimmer, Katherine J. Selzler, Sonja M. Bragg , et al. · 2019

ClinicalTrials.gov identifiers: NCT02245737 and NCT02783573.

P4‐640: DISEASE PROGRESSION AND COSTS AT 1‐YEAR FOLLOW‐UP OF GERAS‐US: A 3‐YEAR STUDY OF MILD COGNITIVE IMPAIRMENT AND MILD DEMENTIA DUE TO ALZHEIMER'S DISEASE IN THE UNITED STATES Open

Julie Chandler, Anthony J. Zagar, Yongin Kim, Brandy R. Matthews, R.L. Robinson , et al. · 2019

GERAS-US aims to understand long-term clinical and economic outcomes of Alzheimer's Disease (AD). Current objective is to describe changes in total costs at 6-months and 12-months post-baseline in amyloid positive[+] patients with mild cog…

Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials Open

J. Scott Andrews, Urvi Desai, Noam Y. Kirson, Miriam L. Zichlin, Daniel Ball , et al. · 2019

Introduction This study estimated the minimal clinically important difference (MCID) for Mini Mental State Examination, Clinical Dementia Rating Scale sum of boxes, and Functional Activities Questionnaire across the Alzheimer's disease (AD…

Statistical tests and identifiability conditions for pooling and analyzing multisite datasets Open

Hao Zhou, Vikas Singh, Sterling C. Johnson, Grace Wahba, Adam Fleisher , et al. · 2018

When sample sizes are small, the ability to identify weak (but scientifically interesting) associations between a set of predictors and a response may be enhanced by pooling existing datasets. However, variations in acquisition methods and…

Clinicopathological correlations in behavioural variant frontotemporal dementia Open

David C. Perry, Jesse A. Brown, Katherine L. Possin, Samir Datta, Andrew Trujillo , et al. · 2017

Accurately predicting the underlying neuropathological diagnosis in patients with behavioural variant frontotemporal dementia (bvFTD) poses a daunting challenge for clinicians but will be critical for the success of disease-modifying thera…

2307 Open

Joey A. Contreras, Shannon L. Risacher, Mario Džemidžić, John D. West, Brenna C. McDonald , et al. · 2017

OBJECTIVES/SPECIFIC AIMS: Recent evidence from resting-state fMRI studies have shown that brain network connectivity is altered in patients with neurodegenerative disorders. However, few studies have examined the complete connectivity patt…

On the path to 2025: understanding the Alzheimer’s disease continuum Open

Paul Aisen, Jeffrey L. Cummings, Clifford R. Jack, John C. Morris, Reisa A. Sperling , et al. · 2017

Basic research advances in recent years have furthered our understanding of the natural history of Alzheimer's disease (AD). It is now recognized that pathophysiological changes begin many years prior to clinical manifestations of disease …

[P4–488]: THE INTEGRATED ALZHEIMER's DISEASE RATING SCALE (IADRS): FINDINGS FROM THE EXPEDITION3 TRIAL Open

Alette M. Wessels, Brandy R. Matthews, Sherie A. Dowsett, Scott W. Andersen, Eric Siemers · 2017

The Integrated Alzheimer's Disease Rating Scale (iADRS) is a composite tool that combines scores from 2 widely accepted measures, the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Alzheimer's Disease Cooperativ…

Mining Outcome-relevant Brain Imaging Genetic Associations via Three-way Sparse Canonical Correlation Analysis in Alzheimer’s Disease Open

Xiaoke Hao, Chanxiu Li, Lei Du, Xiaohui Yao, Jingwen Yan , et al. · 2017

Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits Open

Yuetiva Deming, Jian Xia, Yefei Cai, Jenny Lord, Jorge L. Del‐Aguila , et al. · 2016

Memory Dysfunction Open

Brandy R. Matthews · 2015

Episodic memory, the ability to recall personal episodes, is the subtype of memory most often perceived as dysfunctional by patients and informants. Medial temporal lobe structures, especially the hippocampal formation and associated corti…

Characterizing neurodegeneration in the human connectome: a network science study of hereditary diffuse leukoencephalopathy with spheroids Open

Joey A. Contreras, Shannon L. Rishacher, John D. West, Yu‐Chien Wu, Yang Wang , et al. · 2015

Apolipoprotein ε4 Is Associated with Lower Brain Volume in Cognitively Normal Chinese but Not White Older Adults Open

Jennifer S. Yokoyama, Allen K. L. Lee, Leonel Tadao Takada, Edgar Busovaca, Luke W. Bonham , et al. · 2015

Studying ethnically diverse groups is important for furthering our understanding of biological mechanisms of disease that may vary across human populations. The ε4 allele of apolipoprotein E (APOE ε4) is a well-established risk factor for …

Brandy R. Matthews YOU? Author Swipe